Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Stock Up 8.2 %

Shares of NASDAQ:BPTH opened at $0.98 on Thursday. The business has a 50-day moving average of $1.01 and a two-hundred day moving average of $1.74. Bio-Path has a fifty-two week low of $0.85 and a fifty-two week high of $13.69.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same period in the prior year, the company posted ($10.60) EPS. On average, equities analysts predict that Bio-Path will post -6.2 EPS for the current fiscal year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.